Literature DB >> 19878304

Functional significance of five noncanonical Ca2+-binding sites of human transglutaminase 2 characterized by site-directed mutagenesis.

Róbert Király1, Eva Csosz, Tibor Kurtán, Sándor Antus, Krisztián Szigeti, Zsófia Simon-Vecsei, Ilma Rita Korponay-Szabó, Zsolt Keresztessy, László Fésüs.   

Abstract

The multifunctional tissue transglutaminase 2 (TG2) has a four-domain structure with several Ca(2+)-regulated biochemical activities, including transglutamylation and GTP hydrolysis. The structure of the Ca(2+)-binding form of the human enzyme is not known, and its Ca(2+)-binding sites have not been fully characterized. By mutagenesis, we have targeted its active site Cys, three sites based on homology to Ca(2+)-binding residues of epidermal transglutaminase and factor XIIIa (S1-S3), and two regions with negative surface potentials (S4 and S5). CD spectroscopy, antibody-binding assay and GTPase activity measurements indicated that the amino acid substitutions did not cause major structural alterations. Calcium-45 equilibrium dialysis and isothermal calorimetric titration showed that both wild-type and active site-deleted enzymes (C277S) bind six Ca(2+). Each of the S1-S5 mutants binds fewer than six Ca(2+), S1 is a strong Ca(2+)-binding site, and mutation of one site resulted in the loss of more than one bound Ca(2+), suggesting cooperativity among sites. All mutants were deficient in transglutaminase activity, and GTP inhibited remnant activities. Like those of the wild-type enzyme, the GTPase activities of the mutants were inhibited by Ca(2+), except in the case of the S4 and S5 mutants, which exhibited increased activity. TG2 is the major autoantigen in celiac disease, and testing the reactivity of mutants with autoantibodies from celiac disease patients revealed that S4 strongly determines antigenicity. It can be concluded that five of the Ca(2+)-binding sites of TG2 influence its transglutaminase activity, two sites are involved in the regulation of GTPase activity, and one determines antigenicity for autoantibodies in celiac patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878304     DOI: 10.1111/j.1742-4658.2009.07420.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  30 in total

Review 1.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

2.  An unprecedented dual antagonist and agonist of human Transglutaminase 2.

Authors:  Michael C Yi; Brad A Palanski; Steven A Quintero; Nicholas M Plugis; Chaitan Khosla
Journal:  Bioorg Med Chem Lett       Date:  2015-05-15       Impact factor: 2.823

Review 3.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

Review 4.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 5.  Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.

Authors:  Manuela Basso; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

Review 6.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

Review 7.  Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes.

Authors:  Breandan R Quinn; Laura Yunes-Medina; Gail V W Johnson
Journal:  J Neurosci Res       Date:  2018-03-23       Impact factor: 4.164

Review 8.  Substrates, inhibitors, and probes of mammalian transglutaminase 2.

Authors:  Ruize Zhuang; Chaitan Khosla
Journal:  Anal Biochem       Date:  2019-12-24       Impact factor: 3.365

Review 9.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

10.  Expression of Functional Recombinant Human Tissue Transglutaminase (TG2) Using the Bac-to-Bac Baculovirus Expression System.

Authors:  Yaghoub Yazdani; Shahram Azari; Hamid Reza Kalhor
Journal:  Adv Pharm Bull       Date:  2016-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.